We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.82 USD
-1.17 (-2.66%)
Updated May 17, 2024 04:00 PM ET
After-Market: $42.83 +0.01 (0.02%) 7:58 PM ET
5-Strong Sell of 5 5
A Value C Growth D Momentum B VGM
View All Zacks #1 Ranked Stocks
Zacks News
What's in Store for Quidel (QDEL) This Earnings Season?
by Zacks Equity Research
Strong growth in Cardiac Immunoassay segment's revenues is likely to drive Quidel's (QDEL) top line in Q3.
Can Dental Growth Drive Henry Schein's (HSIC) Q3 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is well placed to gain from the digitalization trend in the global dental market.
What's Setting the Tone for Hologic's (HOLX) Q4 Earnings?
by Zacks Equity Research
Strength in the Breast Health business, Panther system and increasing utilization of Aptima women's health assays will boost Hologic's (HOLX) top line in Q4.
Can R&D Focus Drive DENTSPLY SIRONA's (XRAY) Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) focus on R&D and strategic buyouts to drive Q2 results.
What's in Store for Cardinal Health's (CAH) Q1 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) likely to gain from solid Pharmaceutical revenues in fiscal Q1; medical-gloves sub-segment likely to be soft.
Quidel (QDEL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Quidel (QDEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for INSYS Therapeutics' (INSY) Q3 Earnings?
by Zacks Equity Research
Improvement in prescriptions growth rate of SUBSYS and SYNDROS to drive INSYS Therapeutics' (INSY) Q3 earnings.
3 Medical Product Stocks to Trump Estimates in Q3 Earnings
by Zacks Equity Research
Here we analyze the favorable factors that are likely to boost results of medical product companies in Q3.
What's in Store for Tandem Diabetes' (TNDM) Q3 Earnings?
by Zacks Equity Research
Strong domestic sales along with the recent launch of the t:slim X2 Insulin Pump in selected international markets likely to drive Tandem Diabetes' (TNDM) Q3 earnings.
Can BD Medical Drive Becton, Dickinson's (BDX) Q4 Earnings?
by Zacks Equity Research
Becton, Dickinson (BDX) likely to gain from strong segmental contributions in fiscal Q4.
Why Quidel (QDEL) Could Beat Earnings Estimates Again
by Zacks Equity Research
Quidel (QDEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Are Options Traders Betting on a Big Move in Quidel (QDEL) Stock?
by Zacks Equity Research
Investors need to pay close attention to Quidel (QDEL) stock based on the movements in the options market lately.
3 MedTech Stocks for Safe Returns as Hurricane Fears Peak
by Sweta Jaiswal
With the hurricane season at the peak, we bring three safe picks for investors.
3 Top Stocks From the Booming US Medical Products Industry
by Sreyoshi Mukherjee
The U.S. Medical Products industry is sturdy on solid focus on technological advancement.
Medical - Products Stock Outlook: Short-Term Pain Inevitable
by Zacks Equity Research
Near-term growth prospects of medical products are being questioned due to trade war apprehensions and President Trump's imposition of fresh tariffs on about $200 billion on Chinese imports.
Agios (AGIO) Assigns Ex-Celgene Executive to CEO Position
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) names Dr. Jacqualyn Fouse as its next chief executive officer from Feb 1, 2019 onward.
Implied Volatility Surging for Quidel (QDEL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Quidel (QDEL) stock based on the movements in the options market lately.
Quidel (QDEL) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Quidel (QDEL) delivered earnings and revenue surprises of 63.64% and 0.98%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Quidel (QDEL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Quidel (QDEL) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Quidel (QDEL) Stock?
by Zacks Equity Research
Investors in Quidel (QDEL) need to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging for Quidel (QDEL) Stock Options
by Zacks Equity Research
Quidel (QDEL) needs investors to pay close attention to the stock based on moves in the options market lately.
Options Traders Expect Huge Moves in Quidel (QDEL) Stock
by Zacks Equity Research
Surging implied volatility makes Quidel (QDEL) stock lucrative to the option traders.
Implied Volatility Surging for Quidel (QDEL) Stock Options
by Zacks Equity Research
Investors in Quidel (QDEL) need to pay close attention to the stock based on moves in the options market lately.
Top Ranked Momentum Stocks to Buy for October 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 16th:
5 MedTech Momentum Picks Investors Will Love
by Zacks Equity Research
In a volatile political environment, seasoned investors should focus on momentum stocks as winning bets to tide over the uncertainty.